Sotera Health (NASDAQ:SHC) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Sotera Health (NASDAQ:SHC) by 61.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,921 shares of the company’s stock after acquiring an additional 9,090 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Sotera Health were worth $403,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Hawk Ridge Capital Management LP lifted its stake in shares of Sotera Health by 26.9% in the 3rd quarter. Hawk Ridge Capital Management LP now owns 2,830,614 shares of the company’s stock worth $42,403,000 after acquiring an additional 600,600 shares during the period. Untitled Investments LP boosted its stake in Sotera Health by 39.9% during the 3rd quarter. Untitled Investments LP now owns 958,595 shares of the company’s stock valued at $14,360,000 after purchasing an additional 273,520 shares in the last quarter. William Blair Investment Management LLC increased its position in shares of Sotera Health by 7.9% during the 3rd quarter. William Blair Investment Management LLC now owns 2,116,316 shares of the company’s stock valued at $31,702,000 after purchasing an additional 154,670 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Sotera Health by 13.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,192,275 shares of the company’s stock worth $17,860,000 after buying an additional 143,112 shares in the last quarter. Finally, Repertoire Partners LP acquired a new stake in shares of Sotera Health in the third quarter valued at $2,097,000. Institutional investors own 91.03% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on SHC shares. Citigroup raised Sotera Health from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $18.00 to $16.00 in a report on Wednesday, April 3rd. Jefferies Financial Group raised shares of Sotera Health from a “hold” rating to a “buy” rating and increased their target price for the company from $15.00 to $15.50 in a research note on Monday, March 25th. KeyCorp started coverage on shares of Sotera Health in a research report on Tuesday, February 6th. They issued a “sector weight” rating on the stock. TheStreet upgraded Sotera Health from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $20.00 target price on shares of Sotera Health in a report on Monday, March 4th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Sotera Health currently has an average rating of “Moderate Buy” and an average target price of $17.70.

Sotera Health Price Performance

NASDAQ SHC opened at $11.02 on Friday. Sotera Health has a 52-week low of $10.71 and a 52-week high of $19.40. The company has a debt-to-equity ratio of 5.16, a current ratio of 2.42 and a quick ratio of 2.21. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of 61.22 and a beta of 2.08. The company has a 50 day simple moving average of $12.56 and a 200-day simple moving average of $14.03.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Sotera Health had a return on equity of 51.32% and a net margin of 4.90%. The business had revenue of $310.24 million during the quarter, compared to analyst estimates of $302.17 million. During the same period in the previous year, the company earned $0.23 EPS. The firm’s revenue was up 23.3% on a year-over-year basis. Equities research analysts predict that Sotera Health will post 0.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sotera Health news, Director Pincus & Co. Warburg sold 16,594,363 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $237,465,334.53. Following the completion of the sale, the director now owns 88,822,952 shares of the company’s stock, valued at $1,271,056,443.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Michael P. Rutz sold 83,109 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $1,189,289.79. Following the sale, the insider now directly owns 544,409 shares of the company’s stock, valued at $7,790,492.79. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pincus & Co. Warburg sold 16,594,363 shares of Sotera Health stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $237,465,334.53. Following the completion of the transaction, the director now owns 88,822,952 shares in the company, valued at $1,271,056,443.12. The disclosure for this sale can be found here. Company insiders own 55.12% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.